ArticleJournal of inflammation research2025
Recurrence of Rosacea Induced by Compound Vitamin Tablets: A Case Report.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vitamin BNutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a case of rosacea recurrence in a 37-year-old woman associated with the intake of compound vitamin tablets during the preconception period, with a Naranjo score of 7. These tablets, commonly used for nutritional supplementation to prevent anemia, contain a variety of vitamins, minerals, and trace elements. Despite their widespread use, reports of such supplements causing rosacea recurrence are rare. In this case, the patient experienced a recurrence of facial redness, stinging, and burning after taking the tablets on two separate occasions. Skin dermatoscopy, VISIA imaging, Clinician's Erythema Assessment (CEA), Investigator's Global Assessment (IGA), and Visual Analogue Scale (VAS) all confirmed the recurrence of rosacea. Given her intention to conceive, symptomatic treatment with emollient and reparative dressings was administered. The patient's symptoms gradually resolved after discontinuing the medication, with no recurrence observed during follow-up visits. Women with a history of rosacea should avoid these tablets during preconception, pregnancy, and lactation to prevent recurrence and should choose supplements carefully to minimize the risk of rosacea flare-ups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.